1. Efficacy of Gonadotropin-Releasing Hormone Agonists to Induce Ovulation Following Low-Dose Human Menopausal Gonadotropin Stimulation
- Author
-
J.H. Check and B.S. Shanis
- Subjects
endocrine system ,medicine.medical_specialty ,medicine.drug_class ,media_common.quotation_subject ,Stimulation ,Gonadotropin-releasing hormone ,Biology ,Oocyte ,Human chorionic gonadotropin ,Andrology ,medicine.anatomical_structure ,Endocrinology ,Internal medicine ,HMG-CoA reductase ,medicine ,biology.protein ,Gonadotropin ,Luteinizing hormone ,Ovulation ,hormones, hormone substitutes, and hormone antagonists ,media_common - Abstract
Publisher Summary Conventional human menopausal gonadotropin (hMG) therapy requires the use of an additional injection of human chorionic gonadotropin (hCG) because the high levels of estradiol (E2) generated by gonadotropin therapy suppress the endogenous luteinizing hormone (LH) surge. This chapter provides an overview of the study to evaluate leuprolide acetate (LA) vs hCG when ultralow dose hMG stimulation is given to determine if the incidence of LUF following hCG is lower than previously reported when conventional hMG was used and to see if the superiority of LA over hCG to release oocytes when conventional hMG was used is lost when an ultralow dose regimen is used. The reason ultralow dose gonadotropin regimens produce higher PRs may be related to a lower incidence of LUF when hCG is used for oocyte release. The midcycle LH is needed not only to release the oocyte but also to advance the process of meiosis. The fact that the PR following LA is at least as good as the PR following hCG suggests that a GnRHa is effective in oocyte maturation. The use of LA is logical in women treated with GnRHa down-regulation followed by hMG.
- Published
- 1995